- Home
- NTLA vs MGIC Comparison
NTLA vs MGIC Comparison
Compare NTLA & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- MGIC
- Stock Information
- Founded
- NTLA 2014
- MGIC 1983
- Country
- NTLA United States
- MGIC Israel
- Employees
- NTLA N/A
- MGIC N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MGIC Computer Software: Prepackaged Software
- Sector
- NTLA Health Care
- MGIC Technology
- Exchange
- NTLA Nasdaq
- MGIC Nasdaq
- Market Cap
- NTLA 1.2B
- MGIC 990.3M
- IPO Year
- NTLA 2016
- MGIC 1991
- Fundamental
- Price
- NTLA $12.27
- MGIC $20.46
- Analyst Decision
- NTLA Buy
- MGIC Buy
- Analyst Count
- NTLA 20
- MGIC 2
- Target Price
- NTLA $25.83
- MGIC $18.00
- AVG Volume (30 Days)
- NTLA 9.7M
- MGIC 26.1K
- Earning Date
- NTLA 11-06-2025
- MGIC 11-17-2025
- Dividend Yield
- NTLA N/A
- MGIC 2.99%
- EPS Growth
- NTLA N/A
- MGIC 16.93
- EPS
- NTLA N/A
- MGIC 0.78
- Revenue
- NTLA $52,857,000.00
- MGIC $584,528,000.00
- Revenue This Year
- NTLA $9.20
- MGIC $11.72
- Revenue Next Year
- NTLA N/A
- MGIC $6.24
- P/E Ratio
- NTLA N/A
- MGIC $26.57
- Revenue Growth
- NTLA 14.99
- MGIC 11.98
- 52 Week Low
- NTLA $5.90
- MGIC $10.42
- 52 Week High
- NTLA $28.25
- MGIC $22.00
- Technical
- Relative Strength Index (RSI)
- NTLA 32.04
- MGIC 55.61
- Support Level
- NTLA $13.21
- MGIC $20.52
- Resistance Level
- NTLA $26.35
- MGIC $20.98
- Average True Range (ATR)
- NTLA 1.91
- MGIC 0.47
- MACD
- NTLA -1.94
- MGIC 0.01
- Stochastic Oscillator
- NTLA 3.07
- MGIC 68.59
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.